Cargando…
Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646112/ http://dx.doi.org/10.1186/2051-1426-3-S2-P157 |
| _version_ | 1782400917092433920 |
|---|---|
| author | Kelly, Ronan J Chung, Ki Gu, Yu Steele, Keith E Rebelatto, Marlon C Robbins, Paul B Tavakkoli, Fatemeh Karakunnel, Joyson J Lai, Dominic W Almhanna, Khaldoun |
| author_facet | Kelly, Ronan J Chung, Ki Gu, Yu Steele, Keith E Rebelatto, Marlon C Robbins, Paul B Tavakkoli, Fatemeh Karakunnel, Joyson J Lai, Dominic W Almhanna, Khaldoun |
| author_sort | Kelly, Ronan J |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4646112 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46461122015-11-20 Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma Kelly, Ronan J Chung, Ki Gu, Yu Steele, Keith E Rebelatto, Marlon C Robbins, Paul B Tavakkoli, Fatemeh Karakunnel, Joyson J Lai, Dominic W Almhanna, Khaldoun J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4646112/ http://dx.doi.org/10.1186/2051-1426-3-S2-P157 Text en Copyright © 2015 Kelly et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Kelly, Ronan J Chung, Ki Gu, Yu Steele, Keith E Rebelatto, Marlon C Robbins, Paul B Tavakkoli, Fatemeh Karakunnel, Joyson J Lai, Dominic W Almhanna, Khaldoun Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma |
| title | Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma |
| title_full | Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma |
| title_fullStr | Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma |
| title_full_unstemmed | Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma |
| title_short | Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma |
| title_sort | phase ib/ii study to evaluate the safety and antitumor activity of durvalumab (medi4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646112/ http://dx.doi.org/10.1186/2051-1426-3-S2-P157 |
| work_keys_str_mv | AT kellyronanj phaseibiistudytoevaluatethesafetyandantitumoractivityofdurvalumabmedi4736andtremelimumabasmonotherapyorincombinationinpatientswithrecurrentormetastaticgastricgastroesophagealjunctionadenocarcinoma AT chungki phaseibiistudytoevaluatethesafetyandantitumoractivityofdurvalumabmedi4736andtremelimumabasmonotherapyorincombinationinpatientswithrecurrentormetastaticgastricgastroesophagealjunctionadenocarcinoma AT guyu phaseibiistudytoevaluatethesafetyandantitumoractivityofdurvalumabmedi4736andtremelimumabasmonotherapyorincombinationinpatientswithrecurrentormetastaticgastricgastroesophagealjunctionadenocarcinoma AT steelekeithe phaseibiistudytoevaluatethesafetyandantitumoractivityofdurvalumabmedi4736andtremelimumabasmonotherapyorincombinationinpatientswithrecurrentormetastaticgastricgastroesophagealjunctionadenocarcinoma AT rebelattomarlonc phaseibiistudytoevaluatethesafetyandantitumoractivityofdurvalumabmedi4736andtremelimumabasmonotherapyorincombinationinpatientswithrecurrentormetastaticgastricgastroesophagealjunctionadenocarcinoma AT robbinspaulb phaseibiistudytoevaluatethesafetyandantitumoractivityofdurvalumabmedi4736andtremelimumabasmonotherapyorincombinationinpatientswithrecurrentormetastaticgastricgastroesophagealjunctionadenocarcinoma AT tavakkolifatemeh phaseibiistudytoevaluatethesafetyandantitumoractivityofdurvalumabmedi4736andtremelimumabasmonotherapyorincombinationinpatientswithrecurrentormetastaticgastricgastroesophagealjunctionadenocarcinoma AT karakunneljoysonj phaseibiistudytoevaluatethesafetyandantitumoractivityofdurvalumabmedi4736andtremelimumabasmonotherapyorincombinationinpatientswithrecurrentormetastaticgastricgastroesophagealjunctionadenocarcinoma AT laidominicw phaseibiistudytoevaluatethesafetyandantitumoractivityofdurvalumabmedi4736andtremelimumabasmonotherapyorincombinationinpatientswithrecurrentormetastaticgastricgastroesophagealjunctionadenocarcinoma AT almhannakhaldoun phaseibiistudytoevaluatethesafetyandantitumoractivityofdurvalumabmedi4736andtremelimumabasmonotherapyorincombinationinpatientswithrecurrentormetastaticgastricgastroesophagealjunctionadenocarcinoma |